Use of serum homocysteine to predict cardiovascular disease in Korean men with or without metabolic syndrome

Journal of Korean Medical Science

Volumn 27, Issue 5, 2012, Pages 500-505

  Kang, Ji Yeon ^a   Park, Ill Keun ^a   Lee, Ji Young ^a   Sung, Sook Hee ^a   Chang, Youn Koun ^a   Park, Yoo Kyoung ^b   Choi, Tae In ^a  

^a Korea Hydro & Nuclear Power Co   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Cardiovascular Diseases; Cut off Points; Homocysteine; Metabolic Syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DIET SUPPLEMENTATION; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE; SOUTH KOREA; STATISTICAL MODEL;

ADULT; AREA UNDER CURVE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPUBLIC OF KOREA;

EID: 84862840434     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.5.500     Document Type: Article

References (40)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
2. Hamer M, Stamatakis E. Physical activity and risk of cardiovascular disease events: inflammatory and metabolic mechanisms. Med Sci Sports Exerc 2009; 41: 1206-11.
3. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-14.
5. Ozkan Y, Ozkan E, Simşek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002; 82: 269-77.
6. Sun Y, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese: 12-year prospective cohort study. Circ J 2009; 73: 1423-30.
7. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-98.
8. Rossi GP, Maiolino G, Seccia TM, Burlina A, Zavattiero S, Cesari M, Sticchi D, Pedon L, Zanchetta M, Pessina AC. Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. J Hypertens 2006; 24: 851-9.
9. Shin KP, Lee SY, Kim YJ, Lee JG, Kim DH, Jung DW, Yi YH, Park SK, Cho YH. The association of homocysteine and metabolic syndrome. Korean J Obes 2011; 20: 16-22.
10. Fallon UB, Elwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD. Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health 2001; 55: 91-6.
11. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
12. Björck J, Hellgren M, Råstam L, Lindblad U. Associations between serum insulin and homocysteine in a Swedish population: a potential link between the metabolic syndrome and hyperhomocysteinemia: the Skaraborg project. Metabolism 2006; 55: 1007-13.
13. Choi JW, Kim SH, Yeon CH, Jung KC. The association between homocysteine and features of the metabolic syndrome. Kwandong Med J 2006; 10: 31-7.
14. Nabipour I, Ebrahimi A, Jafari SM, Vahdat K, Assadi M, Movahed A, Moradhaseli F, Obeidi N, Sanjdideh Z. The metabolic syndrome is not associated with homocysteinemia: the Persian Healthy Heart Study. J Endocrinol Invest 2009; 32: 406-10.
15. Lim DM, Park KY, Koh GP. The biochemical markers of coronary heart disease correlates better to metabolic syndrome defined by WHO than by NCEP-ATP III or IDF in Korean type 2 diabetic patients. Korean Diabetes J 2008; 32: 157-64.
16. Lim DM, Park KY, Kim BJ, Lee KW, Lee MJ, Yom YS, Koh GP. Cardiovascular risk according to the components of metabolic syndrome in type 2 diabetes. Korean Clin Diabetes 2009; 10: 196-203.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
18. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
19. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med 1996; 15: 969-86.
20. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitave assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
21. Das M, Ghose M, Borah NC, Choudhury N. A community based study of the relationship between homocysteine and some of the life style factors. Indian J Clin Biochem 2010; 25: 295-301.
22. Kim SJ, Lim KS, Song MS, Kang YJ, Lee SY. Prevalence of hyperhomocysteinemia and related factors in a community-based health examination survey: a cross-sectional study. J Prev Med Public Health 2009; 42: 337-42.
23. Chew SC, Khor GL, Loh SP. Association between dietary folate intake and blood status of folate and homocysteine in Malaysian adults. J Nutr Sci Vitaminol (Tokyo) 2011; 57: 150-5.
24. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Famingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-21.
25. Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis 2011; 214: 11-9.
26. Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J 2009; 61: 156-9.
27. Real JT, Martinez-Hervas S, Garcia-Garcia AB, Chaves FJ, Civera M, Ascaso JF, Carmena R. Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2009; 16: 815-20.
28. Veerkamp MJ, de Graaf J, den Heijer M, Blom HJ, Stalenhoef AF. Plasma homocysteine in subjects with familial combined hyperlipidemia. Atherosclerosis 2003; 166: 111-7.
29. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocininduced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998; 47: 1967-70.
30. Pitla S, Nagalla B. Gender-related difference in the relationship between plasma homocysteine, anthropometric and conventional biochemical coronary heart disease risk factors in middle-aged Indians. Ann Nutr Metab 2009; 54: 1-6.
31. Koehler KM, Romero LJ, Stauber PM, Pareo-Tubbeh SL, Liang HC, Baumgartner RN, Garry PJ, Allen RH. Vitamin supplementation and other variables affecting serum homocysteine and methylmalonic acid concentrations in elderly men and women. J Am Coll Nutr 1996; 15: 364-76.
32. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvåle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteint Study. JAMA 1995; 274: 1526-33.
33. Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett 2009; 583: 1215-25.
34. Namekata K, Enokodi Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia. J Biol Chem 2004; 279: 52961-9.
35. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157: S40-4.
36. Brouwer IA, van Dusseldorp M, Thomas CM, Duran M, Hautvast JG, Eskes TK, Steegers-Theunissen RP. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial. Indian Heart J 2000; 52: S53-8.
37. Chang NS, Kim JM, Kim HS, Cho YW. Plasma total homocysteine and macrovascular complications are associated with food and nutrient intake in patients with type II diabetes mellitus. Nutr Res Pract 2007; 1: 79-83.
38. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
39. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, Turner RM, Thompson SG, Kooner JS. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian, Asian and European men. Lancet 2000; 355: 523-7.
40. Shahram F, Faridar A, Hamedani MG, Nadji A, Naderi N, Mojarad Shafiee N, Rasker JJ, Davatchi F. Plasma homocysteine level in patients with Behcet's disease with or without thrombosis. Arch Iran Med 2010; 13: 476-81.